Diabetic foot ulcers: effects of hyperoxia and SDF-1α on endothelial progenitor cells

References

• Lazarus GS, Cooper DM, Knighton DR et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch. Dermatol.130(4), 489–493 (1994).
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Velazquez OC. Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. Antioxid. Redox Signal.10(11), 1869–1882 (2008).
   PubMed Web of Science ®Google Scholar
• Velazquez OC. Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing. J. Vasc. Surg.45(Suppl A), A39–A47 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, Gallagher KA, Bauer SM et al. Endothelial progenitor cell release into circulation is triggered by hyperoxia-induced increases in bone marrow nitric oxide. Stem Cells24(10), 2309–2318 (2006).
   PubMed Web of Science ®Google Scholar
• Tepper OM, Capla JM, Galiano RD et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood105(3), 1068–1077 (2005).
   PubMed Web of Science ®Google Scholar
• Leung PC. Diabetic foot ulcers – a comprehensive review. Surgeon5(4), 219–231 (2007).
   PubMed Web of Science ®Google Scholar
• Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient, prevention and treatment. Vasc. Health Risk Manage.3(1), 65–76 (2007).
   PubMedGoogle Scholar
• Reiber GE. Diabetic foot care. Financial implications and practice guidelines. Diabetes Care15(Suppl. 1), 29–31 (1992).
   PubMed Web of Science ®Google Scholar
• Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A Phase III randomized placebo-controlled double-blind study. Diabetes Care21(5), 822–827 (1998).
   PubMed Web of Science ®Google Scholar
• Reiber GE, Vileikyte L, Boyko EJ et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care22(1), 157–162 (1999).
   PubMed Web of Science ®Google Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care21(9), 1414–1431 (1998).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Newton K, Blough D et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care22(3), 382–387 (1999).
   PubMed Web of Science ®Google Scholar
• Bartus CL, Margolis DJ. Reducing the incidence of foot ulceration and amputation in diabetes. Curr. Diab. Rep.4(6), 413–418 (2004).
   PubMedGoogle Scholar
• Kessler L, Bilbault P, Ortega F et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care26(8), 2378–2382 (2003).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Diabetes-related amputations of lower extremities in the Medicare population – Minnesota, 1993–1995. MMWR Morb. Mortal. Wkly Rep.47(31), 649–652 (1998).
   PubMedGoogle Scholar
• Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics2(1), 1–12 (2008).
   PubMedGoogle Scholar
• Lindholm C, Bjellerup M, Christensen OB, Zederfeldt B. A demographic survey of leg and foot ulcer patients in a defined population. Acta Derm. Venereol.72(3), 227–230 (1992).
   PubMed Web of Science ®Google Scholar
• Rathur HM, Boulton AJ. The diabetic foot. Clin. Dermatol.25(1), 109–120 (2007).
   PubMed Web of Science ®Google Scholar
• Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999–2002. Diabetes Care29(6), 1263–1268 (2006).
   PubMed Web of Science ®Google Scholar
• Bakker DJ. Hyperbaric oxygen therapy and the diabetic foot. Diabetes Metab. Res. Rev.16(Suppl. 1), S55–S58 (2000).
   Web of Science ®Google Scholar
• Wetzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J. Invest. Dermatol.115(2), 245–253 (2000).
   PubMed Web of Science ®Google Scholar
• Beer HD, Longaker MT, Werner S. Reduced expression of PDGF and PDGF receptors during impaired wound healing. J. Invest. Dermatol.109(2), 132–138 (1997).
   PubMed Web of Science ®Google Scholar
• Werner S, Breeden M, Hubner G, Greenhalgh DG, Longaker MT. Induction of keratinocyte growth factor expression is reduced and delayed during wound healing in the genetically diabetic mouse. J. Invest. Dermatol.103(4), 469–473 (1994).
   PubMed Web of Science ®Google Scholar
• Gallagher KA, Liu ZJ, Xiao M et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 α. J. Clin. Invest.117(5), 1249–1259 (2007).
   PubMed Web of Science ®Google Scholar
• Fadini GP, Miorin M, Facco M et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of Type 2 diabetes mellitus. J. Am. Coll. Cardiol.45(9), 1449–1457 (2005).
   PubMed Web of Science ®Google Scholar
• Loomans CJ, de Koning EJ, Staal FJ et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of Type 1 diabetes. Diabetes53(1), 195–199 (2004).
   PubMed Web of Science ®Google Scholar
• Tepper OM, Galiano RD, Capla JM et al. Human endothelial progenitor cells from Type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation106(22), 2781–2786 (2002).
   PubMed Web of Science ®Google Scholar
• Lin CD, Allori AC, Macklin JE et al. Topical lineage-negative progenitor-cell therapy for diabetic wounds. Plast. Reconstr. Surg.122(5), 1341–1351 (2008).
   PubMed Web of Science ®Google Scholar
• Amann B, Luedemann C, Ratei R, Schmidt-Lucke JA. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant.18(3), 371–380 (2009).
   PubMedGoogle Scholar
• McFarlin K, Gao X, Liu YB et al. Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen.14(4), 471–478 (2006).
   PubMed Web of Science ®Google Scholar
• Nambu M, Kishimoto S, Nakamura S et al. Accelerated wound healing in healing-impaired db/db mice by autologous adipose tissue-derived stromal cells combined with atelocollagen matrix. Ann. Plast. Surg.62(3), 317–321 (2009).
   PubMed Web of Science ®Google Scholar
• Rogers LC, Bevilacqua NJ, Armstrong DG. The use of marrow-derived stem cells to accelerate healing in chronic wounds. Int. Wound J.5(1), 20–25 (2008).
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Psaila B, Lyden D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol. Med.13(2), 72–81 (2007).
   PubMed Web of Science ®Google Scholar
• Bauer SM, Goldstein LJ, Bauer RJ, Chen H, Putt M, Velazquez OC. The bone marrow-derived endothelial progenitor cell response is impaired in delayed wound healing from ischemia. J. Vasc. Surg.43(1), 134–141 (2006).
   PubMed Web of Science ®Google Scholar
• Majka SM, Jackson KA, Kienstra KA, Majesky MW, Goodell MA, Hirschi KK. Distinct progenitor populations in skeletal muscle are bone marrow derived and exhibit different cell fates during vascular regeneration. J. Clin. Invest.111(1), 71–79 (2003).
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature410(6829), 701–705 (2001).
   PubMed Web of Science ®Google Scholar
• Sata M, Saiura A, Kunisato A et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med.8(4), 403–409 (2002).
   PubMed Web of Science ®Google Scholar
• Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc. Natl Acad. Sci. USA99(18), 11951–11956 (2002).
   PubMed Web of Science ®Google Scholar
• Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science319(5860), 195–198 (2008).
   PubMed Web of Science ®Google Scholar
• Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med.7(11), 1194–1201 (2001).
   PubMed Web of Science ®Google Scholar
• Fujiyama S, Amano K, Uehira K et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ. Res.93(10), 980–989 (2003).
   PubMed Web of Science ®Google Scholar
• Scheubel RJ, Kahrstedt S, Weber H et al. Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes. Exp. Gerontol.41(5), 540–548 (2006).
   PubMedGoogle Scholar
• Brownlee M. Negative consequences of glycation. Metabolism49(2 Suppl. 1), 9–13 (2000).
   PubMed Web of Science ®Google Scholar
• Chen J, Song M, Yu S et al. Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress. Mol. Cell. Biochem. (2009) (Epub ahead of print).
   Google Scholar
• Chen Q, Dong L, Wang L, Kang L, Xu B. Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem. Biophys. Res. Comm.381(2), 192–197 (2009).
   PubMed Web of Science ®Google Scholar
• Wendt T, Tanji N, Guo J et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol.14(5), 1383–1395 (2003).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res.84(5), 489–497 (1999).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta1498(2–3), 99–111 (2000).
   PubMed Web of Science ®Google Scholar
• Sattler M, Winkler T, Verma S et al. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood93(9), 2928–2935 (1999).
   PubMed Web of Science ®Google Scholar
• Vafa O, Wade M, Kern S et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell9(5), 1031–1044 (2002).
   PubMed Web of Science ®Google Scholar
• Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J.17(10), 1289–1291 (2003).
   PubMed Web of Science ®Google Scholar
• Gill M, Dias S, Hattori K et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res.88(2), 167–174 (2001).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kalka C, Masuda H et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med.5(4), 434–438 (1999).
   PubMed Web of Science ®Google Scholar
• Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu. Rev. Physiol.57, 707–736 (1995).
   PubMed Web of Science ®Google Scholar
• Marletta MA, Hurshman AR, Rusche KM. Catalysis by nitric oxide synthase. Curr. Opin. Chem. Biol.2(5), 656–663 (1998).
   PubMed Web of Science ®Google Scholar
• Maulik N, Engelman DT, Watanabe M et al. Nitric oxide/carbon monoxide. A molecular switch for myocardial preservation during ischemia. Circulation94(9 Suppl.), II398–II406 (1996).
   PubMedGoogle Scholar
• Fontana J, Fulton D, Chen Y et al. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ. Res.90(8), 866–873 (2002).
   PubMed Web of Science ®Google Scholar
• Khanna S, Roy S, Maurer M, Ratan RR, Sen CK. Oxygen-sensitive reset of hypoxia-inducible factor transactivation response: prolyl hydroxylases tune the biological normoxic set point. Free Radic. Biol. Med.40(12), 2147–2154 (2006).
   PubMedGoogle Scholar
• Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med.9(11), 1370–1376 (2003).
   PubMed Web of Science ®Google Scholar
• Murohara T, Asahara T, Silver M et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest.101(11), 2567–2578 (1998).
   PubMed Web of Science ®Google Scholar
• Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell109(5), 625–637 (2002).
   PubMed Web of Science ®Google Scholar
• Heissig B, Werb Z, Rafii S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb. Haemost.90(4), 570–576 (2003).
   PubMedGoogle Scholar
• Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ. Res.86(3), E50–E54 (2000).
   Web of Science ®Google Scholar
• Cubbon RM, Kahn MB, Wheatcroft SB. Effects of insulin resistance on endothelial progenitor cells and vascular repair. Clin. Sci.117(5), 173–190 (2009).
   Google Scholar
• Roberts GP, Harding KG. Stimulation of glycosaminoglycan synthesis in cultured fibroblasts by hyperbaric oxygen. Br. J. Dermatol.131(5), 630–633 (1994).
   PubMed Web of Science ®Google Scholar
• Jonsson K, Jensen JA, Goodson WH 3rd et al. Tissue oxygenation, anemia, and perfusion in relation to wound healing in surgical patients. Ann. Surg.214(5), 605–613 (1991).
   PubMed Web of Science ®Google Scholar
• Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J. Diabetes Complications16(2), 153–158 (2002).
   PubMed Web of Science ®Google Scholar
• Hohn DC, MacKay RD, Halliday B, Hunt TK. Effect of O2 tension on microbicidal function of leukocytes in wounds and in vitro. Surg. Forum27(62), 18–20 (1976).
   PubMedGoogle Scholar
• Uhl E, Sirsjo A, Haapaniemi T, Nilsson G, Nylander G. Hyperbaric oxygen improves wound healing in normal and ischemic skin tissue. Plast. Reconstr. Surg.93(4), 835–841 (1994).
   PubMedGoogle Scholar
• Sheikh AY, Gibson JJ, Rollins MD, Hopf HW, Hussain Z, Hunt TK. Effect of hyperoxia on vascular endothelial growth factor levels in a wound model. Arch. Surg.135(11), 1293–1297 (2000).
   PubMed Web of Science ®Google Scholar
• Knighton DR, Hunt TK, Scheuenstuhl H, Halliday BJ, Werb Z, Banda MJ. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science221(4617), 1283–1285 (1983).
   PubMed Web of Science ®Google Scholar
• Bonomo SR, Davidson JD, Yu Y, Xia Y, Lin X, Mustoe TA. Hyperbaric oxygen as a signal transducer: upregulation of platelet derived growth factor-β receptor in the presence of HBO2 and PDGF. Undersea Hyperb. Med.25(4), 211–216 (1998).
   PubMedGoogle Scholar
• Duzgun AP, Satir HZ, Ozozan O, Saylam B, Kulah B, Coskun F. Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J. Foot Ankle Surg.47(6), 515–519 (2008).
   PubMed Web of Science ®Google Scholar
• Brakora MJ, Sheffield PJ. Hyperbaric oxygen therapy for diabetic wounds. Clin. Podiatr. Med. Surg.12(1), 105–117 (1995).
   PubMedGoogle Scholar
• Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG. Stem cell mobilization by hyperbaric oxygen. Am. J. Physiol.290(4), H1378–H1386 (2006).
   PubMed Web of Science ®Google Scholar
• England K, Cotter TG. Direct oxidative modifications of signalling proteins in mammalian cells and their effects on apoptosis. Redox Rep.10(5), 237–245 (2005).
   PubMed Web of Science ®Google Scholar
• Gregg D, de Carvalho DD, Kovacic H. Integrins and coagulation: a role for ROS/redox signaling? Antioxid. Redox Signal.6(4), 757–764 (2004).
   PubMedGoogle Scholar
• Moldovan L, Mythreye K, Goldschmidt-Clermont PJ, Satterwhite LL. Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. Cardiovasc. Res.71(2), 236–246 (2006).
   PubMed Web of Science ®Google Scholar
• Sen CK, Khanna S, Babior BM, Hunt TK, Ellison EC, Roy S. Oxidant-induced vascular endothelial growth factor expression in human keratinocytes and cutaneous wound healing. J. Biol. Chem.277(36), 33284–33290 (2002).
   PubMedGoogle Scholar
• Schafer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, Hocker M. Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J. Biol. Chem.278(10), 8190–8198 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pacheco FR, Deudero JJ, Castellanos MC et al. Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am. J. Physiol.291(3), H1395–H1401 (2006).
   PubMed Web of Science ®Google Scholar
• Berendt AR. Counterpoint: hyperbaric oxygen for diabetic foot wounds is not effective. Clin. Infect. Dis.43(2), 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman HI, Fitzmaurice M, Lefaivre JF, Vecchiolla T, Clarke D. An evidence-based appraisal of the use of hyperbaric oxygen on flaps and grafts. Plast. Reconstr. Surg.117(7 Suppl.), 175S–190S (2006).
   Google Scholar
• Gordillo GM, Roy S, Khanna S et al. Topical oxygen therapy induces vascular endothelial growth factor expression and improves closure of clinically presented chronic wounds. Clin. Exp. Pharmacol. Physiol.35(8), 957–964 (2008).
   PubMed Web of Science ®Google Scholar
• Hinchliffe RJ, Valk GD, Apelqvist J et al. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab. Res. Rev. (24 Suppl. 1), S119–S144 (2008).
   Google Scholar
• Senior C. Treatment of diabetic foot ulcers with hyperbaric oxygen. J. Wound Care9(4), 193–197 (2000).
   PubMedGoogle Scholar
• Wunderlich RP, Peters EJ, Lavery LA. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care23(10), 1551–1555 (2000).
   PubMedGoogle Scholar
• Abidia A, Laden G, Kuhan G et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur. J. Vasc. Endovasc. Surg.25(6), 513–518 (2003).
   PubMed Web of Science ®Google Scholar
• Faglia E, Favales F, Aldeghi A et al. Change in major amputation rate in a center dedicated to diabetic foot care during the 1980s: prognostic determinants for major amputation. J. Diabetes Complications12(2), 96–102 (1998).
   PubMed Web of Science ®Google Scholar
• Faglia E, Favales F, Aldeghi A et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care19(12), 1338–1343 (1996).
   PubMed Web of Science ®Google Scholar
• Zamboni WA, Wong HP, Stephenson LL, Pfeifer MA. Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study. Undersea Hyperb. Med.24(3), 175–179 (1997).
   PubMed Web of Science ®Google Scholar
• Roeckl-Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br. J. Surg.92(1), 24–32 (2005).
   PubMed Web of Science ®Google Scholar
• Kranke P, Bennett M, Roeckl-Wiedmann I, Debus S. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst. Rev. (2), CD004123 (2004).
   Google Scholar
• Lebel D, Gortzak Y, Nyska M, Katz T, Atar D, Etzion Y. [Hyperbaric oxygen therapy for chronic diabetic wounds of the lower limbs – a review of the literature]. Harefuah146(3), 223–227, 244–245 (2007).
   PubMedGoogle Scholar
• Gallagher KA, Goldstein LJ, Thom SR, Velazquez OC. Hyperbaric oxygen and bone marrow-derived endothelial progenitor cells in diabetic wound healing. Vascular14(6), 328–337 (2006).
   PubMed Web of Science ®Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med.10(8), 858–864 (2004).
   PubMed Web of Science ®Google Scholar
• Lapidot T. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann. NY Acad. Sci.938, 83–95 (2001).
   PubMed Web of Science ®Google Scholar
• Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1α plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation110(21), 3300–3305 (2004).
   PubMed Web of Science ®Google Scholar
• Hanft JR, Pollak RA, Barbul A et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J. Wound Care17(1), 30–32, 34–37 (2008).
   PubMedGoogle Scholar
• Richard JL, Parer-Richard C, Daures JP et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care18(1), 64–69 (1995).
   PubMed Web of Science ®Google Scholar
• Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen.7(5), 335–346 (1999).
   PubMed Web of Science ®Google Scholar
• Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast. Reconstr. Surg.117(7 Suppl.), 143S–149S (2006).
   PubMed Web of Science ®Google Scholar
• Galiano RD, Tepper OM, Pelo CR et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am. J. Pathol.164(6), 1935–1947 (2004).
   PubMed Web of Science ®Google Scholar
• Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database Syst. Rev. (3), CD006810 (2009).
   Google Scholar
• Papanas N, Maltezos E. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin. Intervent. Aging3(2), 233–240 (2008).
   PubMed Web of Science ®Google Scholar
• Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv. Res.9, 115 (2009).
   PubMed Web of Science ®Google Scholar
• Attinger CE, Ducic I, Cooper P, Zelen CM. The role of intrinsic muscle flaps of the foot for bone coverage in foot and ankle defects in diabetic and nondiabetic patients. Plast. Reconstr. Surg.110(4), 1047–1054 (2002).
   PubMed Web of Science ®Google Scholar
• Herdrich BJ, Lind RC, Liechty KW. Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds. Cytotherapy10(6), 543–550 (2008).
   PubMed Web of Science ®Google Scholar
• Assmus B, Schachinger V, Teupe C et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation106(24), 3009–3017 (2002).
   PubMed Web of Science ®Google Scholar
• Stamm C, Westphal B, Kleine HD et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet361(9351), 45–46 (2003).
   PubMed Web of Science ®Google Scholar